SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 229 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $199,000 | -85.3% | 26,500 | -82.3% | 0.00% | -100.0% |
| Q3 2021 | $1,352,000 | -60.5% | 150,000 | -47.6% | 0.00% | -66.7% |
| Q2 2021 | $3,424,000 | +257.8% | 286,000 | +274.7% | 0.00% | +200.0% |
| Q1 2021 | $957,000 | -20.8% | 76,321 | -1.4% | 0.00% | 0.0% |
| Q4 2020 | $1,208,000 | +84.4% | 77,420 | +11.8% | 0.00% | – |
| Q3 2020 | $655,000 | +42.1% | 69,232 | +61.4% | 0.00% | – |
| Q2 2019 | $461,000 | -66.3% | 42,900 | -64.0% | 0.00% | -100.0% |
| Q4 2018 | $1,369,000 | -32.5% | 119,217 | -0.3% | 0.00% | 0.0% |
| Q3 2018 | $2,027,000 | -45.6% | 119,600 | -54.4% | 0.00% | -60.0% |
| Q2 2018 | $3,727,000 | +375.4% | 262,468 | +449.0% | 0.01% | +400.0% |
| Q4 2017 | $784,000 | +49.3% | 47,810 | +36.6% | 0.00% | 0.0% |
| Q3 2017 | $525,000 | +70.5% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $308,000 | -54.4% | 35,000 | -76.0% | 0.00% | 0.0% |
| Q3 2016 | $675,000 | +457.9% | 145,800 | +1234.9% | 0.00% | – |
| Q2 2015 | $121,000 | – | 10,922 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |